Jefferies Financial Group Inc. Cassava Sciences Inc Put Options Transaction History

Jefferies Financial Group Inc.

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 May 13, 2024	SELL	$18.44 - $26.41 $6.15 Million - $8.81 Million	-333,700 Reduced 74.39%	114,900 $2.33 Million
Q4 2023 Feb 13, 2024	BUY	$12.64 - $30.11 $305,888 - $728,662	24,200 Added 5.7%	448,600 $10.1 Million
Q3 2023 Nov 14, 2023	SELL	$16.64 - $25.32 $134,784 - $205,092	-8,100 Reduced 1.87%	424,400 $7.06 Million
Q2 2023 Aug 14, 2023	BUY	$21.59 - $27.88 $4.63 Million - $5.98 Million	214,600 Added 98.49%	432,500 $10.6 Million
Q1 2023 May 15, 2023	SELL	$23.46 - $36.44 $13.9 Million - $21.6 Million	-592,700 Reduced 73.12%	217,900 $5.26 Million

Q4 2022 Sep 21, 2023	BUY	$27.82 - $44.16 $10.5 Million - $16.7 Million	378,100 Added 87.42%	810,600 $23.9 Million
Q4 2022 Feb 14, 2023	BUY	$27.82 - $44.16 $22.6 Million - $35.8 Million	810,600 New	810,600 $23.9 Million

172

11.3M

1.61M

1.43M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $473M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Jefferies Financial Group Inc., based on Form 13F filings with the SEC.

Stay updated on Jefferies Financial Group Inc. with notifications on news.